Swiss National Bank
ELVN icon

Swiss National Bank’s Enliven Therapeutics ELVN Stock Holding History

Swiss National Bank’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.52M Hold
64,273
– – ﹤0.01% 1739
2025
Q4 		$990K Buy
64,273
+1,100
+2% +$21.9K ﹤0.01% 2182
2025
Q3 		$1.29M Buy
63,173
+1,300
+2% +$26.2K ﹤0.01% 2053
2025
Q2 		$1.24M Buy
61,873
+20,000
+48% +$379K ﹤0.01% 2040
2025
Q1 		$824K Hold
41,873
– – ﹤0.01% 2212
2024
Q4 		$942K Buy
41,873
+5,100
+14% +$132K ﹤0.01% 2227
2024
Q3 		$939K Hold
36,773
– – ﹤0.01% 2239
2024
Q2 		$859K Hold
36,773
– – ﹤0.01% 2238
2024
Q1 		$647K Buy
36,773
+300
+0.8% +$4.6K ﹤0.01% 2398
2023
Q4 		$505K Sell
36,473
-4,200
-10% -$51.4K ﹤0.01% 2473
2023
Q3 		$556K Sell
40,673
-8,500
-17% -$143K ﹤0.01% 2483
2023
Q2 		$1M Buy
+49,173
New +$994K ﹤0.01% 2290

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Swiss National Bank's ELVN Position: Q1 2026 in Review

Swiss National Bank held its Enliven Therapeutics (ELVN) position steady in Q1 2026 at 64,273 shares worth $2.52M. The position accounts for ﹤0.01% of the portfolio, ranked #1739.

Swiss National Bank first reported a position in ELVN in Q2 2023 and has held it in 12 quarters since. 170 funds tracked by Wall St. Rank hold ELVN as of Q1 2026.

  • Swiss National Bank held 64,273 shares of Enliven Therapeutics worth $2.52M as of Q1 2026.
  • Swiss National Bank left its Enliven Therapeutics share count unchanged in Q1 2026.
  • Enliven Therapeutics made up ﹤0.01% of Swiss National Bank's portfolio in Q1 2026, its #1739 holding.
  • Swiss National Bank first reported a position in Enliven Therapeutics in Q2 2023 and has held it in 12 quarters since.
  • 170 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q1 2026.

Based on Swiss National Bank's 13F filing for Q1 2026, filed 7 May 2026.